Kornimate/medical-research-clean huggingface dataset:
a pilot study - safety and efficacy of nailprotex® for onychomycosis treatment

Conditions: Onychomycosis; Chronic Paronychia

Summary: this study was designed to demonstrate the efficacy of this product in non-dermatophyte (scytalidium dimidiatum) onychomycosis and chronic paronychia treatment in thai patients.

onychomycosis is the common superficial fungal skin infection in general population. according to the previous study, the prevalence of tinea pedis and onychomycosis in general thai population were 3.8% and 1.7% respectively. however, this problem has been neglected for treatment due to asymptomatic clinical manifestations and low effects in quality of life. in thailand, the previous studies reported that the aetiological pathogens of this disorder were non-dermatophyte mold (51.6%), dermatophyte (36.3%) and yeast (6%). additionally, scytalidium dimidiatum was the majority causative agents in non-dermatophyte mold. systemic therapy such as azoles group and terbinafine is recommended for the standard management of tinea capitis. in contrast, a prolonged course may be induce serious side effects. so that topical therapy is the alternative treatment in older patients who are limited in drug usage. especially, non-dermatophyte onychomycosis is the recalcitrant condition. moreover, none of the standard regimen is recommended. nailprotex® is the novel topical treatment in onychomycosis and chronic paronychia. the active ingredient is phenol which is extracted from olea european leaf. it is able to inhibit the fungal growth. additionally, this product has been applied for nail care in many european countries over 10 years. the serious side effects have never been reported. therefore, this study was designed to demonstrate the efficacy of this product in non-dermatophyte (scytalidium dimidiatum) onychomycosis and chronic paronychia treatment in thai patients.

Eligibility criteria:
inclusion criteria: * male or female participants was 18 years old or above. * participants were diagnosed scytalidium dimidiatum onychomycosis or chronic paronychia by dermatologists based on clinical presentation and mycological identification. * participants accept the aim of this project and sign the consent form by themselves. exclusion criteria: * participants have other nail disorders before participate the research. * participants have the history of immunocompromised host. * participants were diagnosed onychomycosis more than 3 nails or matrix involvement.

Keywords: onychomycosis chronic paronychia treatment
effects of food advanced glycation endproducts on vascular function in diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: recent evidence supports detrimental effects of advanced glycation endproducts (age) on vascular function (vf). though, the effect of age-modified proteins alone on vascular function remained unknown. therefore, the aim of our study is to investigate the effects of heat-treated, glycated beta-lactoglobulins (blg) on vascular function in subjects with type 2 diabetes mellitus (t2dm) and to compare it to non-glycated, heat-treated blg.

in a double-blind, controlled, randomized, cross-over manner, 19 subjects with t2dm will receive on 2 different days beverages containing either glycated, heat-treated blg or non-glycated, heat-treated blg. macrovascular (brachial ultrasound of flow mediated dilatation -fmd) and microvascular function (laser-doppler measurements of reactive hyperemia at the hand) at baseline (t0), as well as 90 (t90) and 180 (t180) minutes after each beverage will be measured.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus exclusion criteria: * other types of diabetes * major cardiovascular complications within 6 months prior to screening * major diabetes complications * failure to give informed consent

Keywords: diabetes advanced glycation endproducts endothelium
lypo-hypertrofia characterization in diabetes

Conditions: Type 1 Diabetes Mellitus

Summary: aim/hypothesis: subcutaneous insulin absorption is one of the factors which strongly influence blood sugar control in patients with diabetes mellitus on insulin therapy. in response, a regular absorption is influenced by lipo-hypertrophy in subcutaneous tissue on injection sites. so far lipo-hypertrophy diagnosis has only been clinical since there are no imaging studies that have characterized precisely morphometry of lipo-hypertrophic tissue. methods: in two groups of 20 type 1 diabetes patients on insulin therapy, lipo-hypertrophy is characterized and defined by clinical tapping or by ultrasound with multi frequency linear probe (6-18 mhz). patients are therefore advised to avoid insulin injections on those areas so defined. patients are reevaluated 3 and 12 months later

an observational study has been carried out, checked with parallel arms in which type 1 diabetes patients are recruited with clinical evidence of lypo-hypertrophy in insulin injected areas. patients attend to the diabetes unit of niguarda ca' granda hospital. obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. in the control group the investigators manage to define the lypo-hypertrophic area by tapping and body inspection. in the study group the investigators can define and mark out the area/areas with lipo-hypertrophy by ultrasound scan test. all the tested patients both the control group and the study group, are discouraged from use insulin in areas where lypo-hypertrophy is present. patients are reassessed after 3 months with a clinical assessment of glucose control by hba1c. after 12 months subcutaneous tissue scan is repeated in 10 patients within the experimental group and a new assessment of hba1c is performed. ultrasound assessment. the scan used is esaote my lab70 linear probe multi-frequency \[6-18 mhz)

Eligibility criteria:
inclusion criteria: * type 1 diabetes * age between 18 and 75 years old * lack of extended cutaneous diseases * bmi \<30 exclusion criteria: * bmi\> 30 * active allergies * cancer * liver failure * kidney failure

Keywords: ultrasound lypo-hypertrophy
eat healthy for families

Conditions: Obesity, Childhood; Energy Density; Diet Quality

Summary: this study investigates the effect of a low energy-density dietary prescription as compared to myplate recommendations in preschool children at risk for obesity.


Eligibility criteria:
inclusion criteria: * the parent is ≥18 years-old with a bmi ≥30 kg/m2 (indicating the child to be at risk for obesity); * the child is 2-5 years-old with a bmi-for-age and sex \<95th percentile; * the parent and child live together ≥50% of the time; * the parent and child are able to read, speak and understand english; * the family has transportation to the university of delaware; and * the family is committed to the 6-month program. exclusion criteria: * the child is participating in a weight management program or seeing a registered dietitian for weight loss; * the child is taking weight loss medication or medication that impacts appetite; or * the child has a medical condition that impacts growth or has a medical condition that requires a specific eating plan.
effect of beta-blocker on cardioprotective effect of remote ischemic conditioning

Conditions: Myocardial Infarction

Summary: remote ischemic conditioning has been shown to protect myocardium from ischemia-reperfusion injury during cardiac intervention or cardiac surgery. however, effect of beta-blocker, commonly used cardiovascular medication in patients with cardiac diseases such as hypertension or angina pectoris, on cardioprotective role of remote ischemic conditioning has not been well documented. the purpose of the study is to investigate the effect of beta-blocker on remote ischemic conditioning in healthy volunteers.

this study is prospective cross-over study investigating effect of beta-blocker on cardioprotective role of remote ischemic conditioning. eleven male healthy volunteers are going to take oral beta-blocker (carvedilol, 12.5 mg once) or not before undergoing remote ischemic conditioning (consisting of 4 cycles of 5-min ischemia and subsequent 5-min reperfusion of upper arm), separated by 6-day wash-out period. to evaluate cardioprotective effect of remote ischemic conditioning, blood samples will be obtained before and after remote ischemic conditioning. form the samples, human dialysate will be obtained and be perfused to rat heart through langendorff apparatus before ischemia-reperfusion injury to the rat heart. changes of infarct size of the rat heart will be compared between the beta-blocker and control groups.

Eligibility criteria:
inclusion criteria: * healthy male volunteer * not taking any medication exclusion criteria: * bmi \ 30 kg/m2 * allergic history of any medication * baseline sbp \> 150 mmhg or \< 100 mmhg * baseline dbp \> 100 mmhg or \< 50 mmhg * strenuous exercise, excessive caffeine or alcohol, smoking 24 h prior to experiment * cannot undergoing remote ischemic conditioning for any reason * refuse to enroll

Keywords: remote ischemic conditioning beta-blocker
postoperative adjuvant therapy of hcc based on pd-1

Conditions: Hepatocellular Carcinoma; RFS

Summary: for the treatment of hepatocellular carcinoma, liver resection is still one of the optimal options, but the recurrence rate is as high as 70% five years after the operation, and the prognosis of patients with high-risk recurrence factors such as portal vein tumor thrombus and microvascular invasion is even worse, so it is particularly urgent to find effective postoperative adjuvant treatment. the role of pd-1 inhibitors in preventing the postoperative recurrence of hcc requires further study.

we conducted a prospective cohort study comparing the efficacy of pd-1-based adjuvant therapy and transarterial chemoembolization in patients with high-risk factors for recurrence undergoing radical surgery. after surgery, patients received the appropriate adjuvant therapy according to the type of high-risk recurrence factor. patients with high-risk factors for recurrence who received pd-1-based adjuvant therapy were included in the exposure cohort; patients with high-risk factors for recurrence who received 1 tace adjuvant therapy were included in the control cohort. the primary endpoint of this study was disease-free survival, and the overall survival and adverse events were considered as the second endpoint.

Eligibility criteria:
inclusion criteria: * 1. in patients with hcc who received r0 resection, there was no bile duct invasion, extrahepatic invasion, and distant metastasis of lung, bone, and brain * 2. patients with high-risk factors for tumor recurrence (tumor diameter ≥ 5cm, multiple tumors, tumor rupture, afp ≥ 400 ng/dl, microvascular invasion, portal vein thrombosis, and poorly differentiated) and received pd-1-based adjuvant therapy or tace adjuvant therapy after the surgery * 3. aged18-75 * 4. eastern cooperative oncology group (ecog) performing status of 0-1 * 5. child-pugh grade a or b * 6. the patient knows, and informed consent was obtained exclusion criteria: * 1. any history of other malignant tumors or recurrent hcc * 2. any preoperative treatment for hcc including local and systemic therapy * 3. any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency * 4. any persistent serious surgery-related complications * 5. any persistent serious surgery-related complications; esophageal and/or gastric variceal bleeding within 6 months * 6. inability or refusal to comply with the treatment and monitoring

Keywords: pd-1 disease-free survival rate adjuvant therapy lenvatinib
role of nutritional intervention for the treatment of sarcopenia in cirrhotic patients with refractory ascites candidate to transjugular intrahepatic portosystemic shunt placement and identification of prognostic factors related to clinical outcome

Conditions: Liver Cirrhosis; Refractory Ascites in Patients with Cirrhosis; Sarcopenia in Liver Cirrhosis

Summary: the hypothesis is that in patients with cirrhosis and refractory ascites candidate to tips, and sarcopenia (identified by a pma ≤16 cm² at the level of l3), who are at high-risk of 6-month mortality after tips placement, a post-tips 12 weeks nutritional intervention is associated with improved post-tips prognosis. the primary objective is to evaluate the effect of a post-tips 12 weeks nutritional intervention on liver transplant-free six-month survival in sarcopenic candidates to tips for refractory ascites in cirrhosis.


Eligibility criteria:
inclusion criteria: * men and women with an age ≥ 18 and ≤ 80 years * clinical, radiological or histological diagnosis of liver cirrhosis * diagnosis of ra * confirmation of sarcopenia defined in ct scan as the sum of the psoas muscle areas measured at the level of the 3rd lumbar vertebra (pma) ≤16 cm2 * informed consent signed exclusion criteria: * severe hepatic insufficiency (bilirubin\> 5 mg/dl, meld score\> 18, child-pugh score\> 9) * congestive heart failure class ≥2 according to new york heart association criteria (nyha) * active coronary heart disease (myocardial infarction within 6 months of the study) * severe pulmonary hypertension suspected on echocardiogram (systolic pulmonary arterial pressure \[paps\]\> 35 mmhg) and confirmed with right cardiac catheterization (paps\> 45mmhg) * chronic renal failure (creatinine\> 3 mg/dl) * performance status ≥2 according to the eastern cooperative oncology group scale (ecog) * history of grade iii-iv hepatic encephalopathy or west haven grade i-ii hepatic encephalopathy episodes within the last 3 months * uncontrolled systemic sepsis * presence of hepatocellular carcinoma * complete portal vein thrombosis * active bleeding from gastroesophageal varices. patients with adequately treated gastroesophageal varices can be included in the study (banding ligation, sclerotherapy) * diagnosis of extra hepatic neoplasia * transplant recipients * patients unable or unwilling to comply with the protocol requirements * pregnant or lactating women * patients unable to autonomously express their consent (incapable patients) * any other laboratory condition or result that in the opinion of the principal investigator, preclude the subject's participation in the study

Keywords: nutritional treatment sarcopenia liver cirrhosis refractory ascites transjugular intrahepatic portosystemic shunt placement tips
collaborative lifestyle intervention program in knee osteoarthritis patients

Conditions: Osteoarthritis

Summary: the collaborative lifestyle intervention program in knee osteoarthritis patients (clip-oa) compares a novel community-based exercise and dietary weight loss program to the arthritis foundation's walk with ease intervention on improved mobility in knee osteoarthritis (oa) patients.

knee oa is a chronic, progressive, degenerative disease that affects over 20 million americans, and is cited as the primary cause for activity restriction and physical disability in older adults. the joint damage and symptoms (i.e., pain, stiffness, and fatigue) accompanying symptomatic knee oa result in activity restriction, muscle atrophy, reduced quality of life and difficulty in performance of functional tasks. despite the well-established benefits of the arthritis foundation's (af) exercise programs, recent evidence suggests that lifestyle interventions combining exercise and dietary weight loss (ex+dwl) results in superior improvements in key clinical outcomes in older, overweight or obese knee oa patients. primary aim: to compare the effects of a novel community-based ex+dwl program to af's walk with ease (wwe) ex intervention on improved mobility in knee osteoarthritis (oa) patients. secondary aim: to compare the cost effectiveness and effects of the ex+dwl and wwe interventions on weight loss, pain, and quality of life.

Eligibility criteria:
inclusion criteria: * diagnosed with knee oa: physician documented radiographic tibiofemoral oa of one or both knees * overweight or obese: bmi \>25 and \<40 * knee pain and risk for mobility disability: self-reported difficulty walking ¼ mile, climbing stairs, lifting or carrying groceries, or performing other household activities due to knee pain * sedentary: sedentary lifestyle defined as currently participating \ 10 min * health status: all participants must be free of severe heart or systemic disease that would make moderate intensity exercise participation unsafe * age: \> 50 years of age * stability of residence: does not plan to move out of the columbus metropolitan area for the duration of the study * consents: willing to give an informed consent and sign a hippa authorization form; (9) physician consent: treating rheumatologist and primary care physician provide medical consent for participation * agreeableness: willing to accept randomization and complete all assessment and intervention procedures exclusion criteria: * health status: any serious medical condition that precludes safe participation in an exercise program * study staff judgment: inability to complete the study protocol, in the opinion of the study staff, due to frailty, illness, or other reasons

Keywords: older adults weight loss exercise knee pain
safety of stool transplant for patients with difficult to treat c. difficile infection

Conditions: C. Difficile Infection; Cancer

Summary: the purpose of this study is to test the safety of fmt in patients with c. difficile and cancer. in previous other studies, fmt has been shown to cure c. difficile when antibiotics have failed, but most of these studies have not included patients with cancer. the investigators want to prove that fmt is safe in this group of people so that doctors will feel more comfortable prescribing it for their patients with cancer.


Eligibility criteria:
inclusion criteria: * ≥18 years old * patients with solid organ malignancy who have received chemotherapy within the past six months. * clinical and microbiologic relapse of c. difficile associated diarrhea after at least one course of adequate antibiotic therapy or refractory disease that does not respond to treatment. * at least 10 days of vancomycin at least 125mg qid, or metronidazole 500mg tid * c. difficile associated diarrhea is defined as: ≥3 loose or watery stools per day for at least 2 consecutive days or ≥8 loose stools in 48 hours and positive clostridium difficile pcr * life expectancy of \>3 months. exclusion criteria: * expected prolonged compromised immunity * hiv infection with cd4 count \<240 * history of hematopoietic stem cell transplant (hsct) * hematologic malignancy * anc \<1000/mm3 * contraindications to anesthesia for procedure * serious cardiopulmonary comorbidities * inability to tolerate anesthesia * hgb \<8 g/dl * risk of bleeding during procedure * plt \<50,000 k/mcl * inr \>1.5 inr * pregnancy o pregnant patients will be excluded from this study. * gastrointestinal (gi) contraindications * inflammatory bowel disease * active fistula * small bowel obstruction * ileus * gastroparesis * nausea and vomiting * gastrointestinal surgery within the previous 3 months

Keywords: safety of stool transplant fecal microbiota transplantation (fmt) 15-337
peripheral blood stem cell transplantation using the clinimacs device

Conditions: Malignant Diseases (ie, Leukemia, MDS, Lymphoma); Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)

Summary: t cell depletion utilizing the clinimacs device will allow more precise, specific and controlled graft engineering of peripheral blood stem cells from unrelated and partially matched related donors without an increase in relapse or graft rejection and grade iii or iv acute graft versus host disease (gvhd).


Eligibility criteria:
inclusion criteria: * all races are eligible * malignant diseases: leukemias and lymphomas * non-malignant diseases: severe aplastic anemia, immunodeficiencies exclusion criteria: * lansky or karnofsky \> 70 * echo \> 27% shortening fraction * renal function:serum creatinine \< 1.5 x for normal age * no active untreated infection * dlco \> 50% of predicted value * hepatic: ast and alt \< 3x upper limit of normal; bilirubin \< 2.0.

Keywords: malignant and non-malignant diseases hematopoietic stem cell transplant peripheral blood progenitor cell transplant clinimacs device t cell depletion
assessment of corneal biomechanics with the corvis st in different age of myopia with orthokeratology

Conditions: Myopia; Orthokeratology

Summary: the present research focused on the effect of the age for the corneal biomechanics of low and moderate myopia patients after wearing orthokeratology (ok lens). according to age, the included cases were divided into 3 groups. through the analysis of corneal biomechanical parameters, further learn the influence of ok lens on the patient cornea. it would help ophthalmologist and optometrist find out the potential issue and reach a better control result.

the present research focused on the effect of the age for the corneal biomechanics of low and moderate myopia patients after wearing orthokeratology (ok lens). according to age, the included cases were divided into 3 groups: ⅰ (8-12 years old), ⅱ (13-16 years old), ⅲ (over 16 years old). the ok lenses used in the present study are of the same design (euclid systems orthokeratology; euclid system, herndon, va, usa). the base line (day 0) and different follow-up time point (day 1, week 1, week 2, month 1, month 3, and month 6) of dynamic corneal response (dcr) (including 19 items) of the patients derived by corvis st were collected. the difference between before and after wearing ok lens and the changes of parameters among the three groups were both analyzed. and the correlation between axis length (al) and the 19 parameters also was analyzed. through the analysis of corneal biomechanical parameters, further learn the influence of ok lens on the patient cornea. it would help ophthalmologist and optometrist find out the potential issue and reach a better control result.

Eligibility criteria:
inclusion criteria: * age from 8 to 40 years old * spherical equivalent(se) was range from -1.00d to -5.00d * conform to the standard of wearing orthokeratology lens exclusion criteria: * ocular diseases and systemic diseases * visual acuity was less than 20/20 * unable to follow visitors on time

Keywords: myopia prevention and control orthokeratology dynamic corneal response